Maraviroc -: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist

被引:8
|
作者
Ginesta, JB [1 ]
Castañer, J [1 ]
Bozzo, J [1 ]
Bayés, M [1 ]
机构
[1] Prous Sci, Barcelona 08080, Spain
关键词
4,4-difIuoro-N-[3-[(1R,3exo,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropy])cyclohexanecarboxamide;
D O I
10.1358/dof.2005.030.05.902712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the availability of several approved drugs for the treatment of human immunodeficiency virus (HIV) infection, the limited effectiveness of current antiretroviral regimens, mainly due to the emergence of resistance, makes the development of new agents necessary. Several novel compounds are being added to existing classes, but newer classes of antiretroviral drugs, such as HIV entry inhibitors, are also under development. Maraviroc is a novel small molecule that specifically antagonizes the chemokine CCR5 receptor required for efficient HIV entry. It displays potent and broad-spectrum anti-HIV activity and excellent pharmacokinetic and safety profiles. All these features and the promising results obtained in early clinical trials make this agent a good candidate for inclusion in combination therapies for HIV treatment. Maraviroc is the most clinically advanced CCR5 antagonist and has just entered phase III clinical trials.
引用
收藏
页码:469 / 477
页数:9
相关论文
共 50 条
  • [31] Recombinant soluble CCR5 AND CXCR4 chemokine receptors as anti-HIV drug targets
    Victoria Kurbatska
    Zhanna Rudevica
    Alexander Tsimanis
    Ainars Leonciks
    Retrovirology, 7
  • [32] Recombinant soluble CCR5 AND CXCR4 chemokine receptors as anti-HIV drug targets
    Kurbatska, Victoria
    Rudevica, Zhanna
    Isimanis, Alexander
    Leonciks, Ainars
    RETROVIROLOGY, 2010, 7 : 28 - 28
  • [33] Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    Westby, Mike
    Smith-Burchnell, Caroline
    Mori, Julie
    Lewis, Marilyn
    Mosley, Michael
    Stockdale, Mark
    Dorr, Patrick
    Ciaramella, Giuseppe
    Perros, Manos
    JOURNAL OF VIROLOGY, 2007, 81 (05) : 2359 - 2371
  • [34] Study of intracellular and immunomodulant effects of CCR5 Antagonist Maraviroc
    Sauzullo, I.
    Mengoni, F.
    Rossi, R.
    Celardo, I.
    Ghibelli, L.
    Lichtner, M.
    Massetti, A. P.
    Mastroianni, C. M.
    Vullo, V.
    INFECTION, 2010, 38 : 92 - 93
  • [35] Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
    Price, David A.
    Armour, Duncan
    de Groot, Marcel
    Leishman, Derek
    Napier, Carolyn
    Perros, Manos
    Stammen, Blanda L.
    Wood, Anthony
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (17) : 4633 - 4637
  • [36] Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc
    Asano, Shigehiro
    Gavrilyuk, Julia
    Burton, Dennis R.
    Barbas, Carlos F., III
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (02): : 133 - 137
  • [37] Bevirimat - Anti-HIV agent viral maturation inhibitor
    Dimeglumine, Bevirimat
    DRUGS OF THE FUTURE, 2007, 32 (01) : 7 - 11
  • [38] Biological Profiling of Anti-HIV Agents and Insight into CCR5 Antagonist Binding Using in silico Techniques
    Carrieri, Antonio
    Perez-Nueno, Violeta I.
    Fano, Alessandra
    Pistone, Carlo
    Ritchie, David W.
    Teixido, Jordi
    CHEMMEDCHEM, 2009, 4 (07) : 1153 - 1163
  • [39] Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
    Kondru, Rama
    Zhang, Jun
    Ji, Changhua
    Mirzadegan, Tara
    Rotstein, David
    Sankuratri, Surya
    Dioszegi, Marianna
    MOLECULAR PHARMACOLOGY, 2008, 73 (03) : 789 - 800
  • [40] Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)
    Garcia-Perez, Javier
    Rueda, Patricia
    Alcami, Jose
    Rognan, Didier
    Arenzana-Seisdedos, Fernando
    Lagane, Bernard
    Kellenberger, Esther
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (38) : 33409 - 33421